Exane Asset Management lessened its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 89.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,758 shares of the biopharmaceutical company’s stock after selling 123,162 shares during the period. Alexion Pharmaceuticals accounts for 0.8% of Exane Asset Management’s portfolio, making the stock its 23rd largest holding. Exane Asset Management’s holdings in Alexion Pharmaceuticals were worth $1,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the stock. NuWave Investment Management LLC grew its holdings in Alexion Pharmaceuticals by 851.9% during the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 460 shares during the period. Benjamin F. Edwards & Company Inc. acquired a new stake in Alexion Pharmaceuticals during the 4th quarter worth $68,000. We Are One Seven LLC acquired a new stake in Alexion Pharmaceuticals during the 4th quarter worth $79,000. Shine Investment Advisory Services Inc. grew its holdings in Alexion Pharmaceuticals by 114.1% during the 4th quarter. Shine Investment Advisory Services Inc. now owns 897 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 478 shares during the period. Finally, First Hawaiian Bank acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $102,000. Hedge funds and other institutional investors own 94.20% of the company’s stock.
In other news, CEO Ludwig Hantson sold 3,244 shares of the company’s stock in a transaction dated Monday, December 31st. The shares were sold at an average price of $95.85, for a total value of $310,937.40. Following the sale, the chief executive officer now directly owns 150,696 shares of the company’s stock, valued at approximately $14,444,211.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Indrani Lall Franchini sold 2,605 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total transaction of $307,728.65. Following the completion of the sale, the executive vice president now directly owns 29,304 shares in the company, valued at $3,461,681.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,093 shares of company stock worth $929,603. 4.35% of the stock is owned by insiders.
A number of analysts have commented on ALXN shares. Credit Suisse Group set a $156.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, December 30th. ValuEngine raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 8th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $134.00 target price for the company in a report on Tuesday, October 30th. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 22nd. Finally, Citigroup decreased their price target on shares of Alexion Pharmaceuticals from $195.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, October 25th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $162.31.
Shares of ALXN stock opened at $120.14 on Monday. The company has a current ratio of 2.88, a quick ratio of 2.48 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $26.85 billion, a PE ratio of 16.94, a PEG ratio of 0.89 and a beta of 1.56. Alexion Pharmaceuticals, Inc. has a 52-week low of $92.56 and a 52-week high of $140.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.54. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. Alexion Pharmaceuticals’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 EPS. As a group, equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.51 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2019/02/11/alexion-pharmaceuticals-inc-alxn-shares-sold-by-exane-asset-management.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
See Also: Earnings Per Share (EPS) Explained
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.